MAP PHARMACEUTICALS, INC. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2013-03-01: Form 8-K; Period of report 2013-03-01; Description 2.01 Completion of Acquisition or Disposition of Assets; 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing; 3.02 Unregistered Sales of Equity Securities; 3.03 Material Modification to Rights of Security Holders; 5.01 Changes in Control of Registrant; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year; Details 2.01.
- 2013-01-30: Form 8-K; Period of report 2013-01-24; Description 1.02 Termination of a Material Definitive Agreement; Details 1.02.
- 2013-01-23: Form 8-K; Period of report 2013-01-22; Description 1.01 Entry into a Material Definitive Agreement; Details 1.01.
- 2012-11-21: Form 8-K; Period of report 2012-11-21; Description 8.01 Other Events; Details 8.01.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2013-03-01 | 8-K | 2013-03-01 | 2.01 Completion of Acquisition or Disposition of Assets; 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing; 3.02 Unregistered Sales of Equity Securities; 3.03 Material Modification to Rights of Security Holders; 5.01 Changes in Control of Registrant; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year | 2.01 On March 1, 2013, Allergan, Inc., a Delaware corporation (“Allergan”), completed its acquisition of all of the outstanding shares of common stock, par value $0.01 per share (the “Shares”), of MAP Pharmaceuticals, Inc., a Delaware corporation (“MAP”), pursuant to an Agreement and Plan of Merger (the “Merger Agreement”), dated as of January 22, 2013, by and among Allergan, Groundhog Acquisition, Inc. (the “Purchaser”) and MAP. 3.01 As a result of the transactions described in Item 2.01 hereof, which are incorporated herein by reference, and pursuant to the Merger Agreement, MAP no longer fulfills the numerical listing requirements of the NASDAQ Global Select Market (“NASDAQ”). 3.02 On March 1, 2013, pursuant to the Merger Agreement, Purchaser exercised its right (the “Top-Up Option”) to purchase directly from the Company 43,120,229 newly-issued Shares (the “Top-Up Option Shares”) at $25.00 per Share, net to the seller in cash, without interest but subject to any applicable tax withholding. 3.03 The information set forth in Item 2.01 of this Current Report on Form 8-K is incorporated herein by reference. 5.01 The information set forth in Item 2.01 and Item 3.02 of this Current Report on Form 8-K is incorporated herein by reference. 5.02 On March 1, 2013 and in connection with the transactions contemplated by the Merger Agreement, Thomas A. Armer, Gerri A. Henwood, Bernard J. Kelley, Matthew V. McPherron, Timothy S. Nelson, W. James O’Shea, Scott R. Ward and H. Ward Wolff resigned as directors of MAP, and David E.I. Pyott, Jeffrey L. Edwards and Arnold A. Pinkston became directors of MAP. 5.03 Pursuant to the Merger Agreement, on the Effective Date, the Company’s certificate of incorporation was amended and restated in its entirety (the “Amended and Restated Certificate of Incorporation”). | d495160d8k.htm |
| 2013-01-30 | 8-K | 2013-01-24 | 1.02 Termination of a Material Definitive Agreement | 1.02 On January 24, 2013, MAP Pharmaceuticals,, Inc. (the “Company,” “us” or “we”) received notice from Exemplar Pharmaceuticals, LLC f/k/a/ Xemplar Pharmaceuticals, LLC, (“Exemplar”) of Exemplar’s termination of the Manufacturing and Supply Agreement between the Company and Exemplar, dated April 26, 2006, as amended (the “Exemplar Agreement”), such termination effective on January 31, 2014. | d476555d8k.htm |
| 2013-01-23 | 8-K | 2013-01-22 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | d474416d8k.htm |
| 2012-11-21 | 8-K | 2012-11-21 | 8.01 Other Events | 8.01 On November 21, 2012, MAP Pharmaceuticals, Inc. (the “Company”) announced that the Company’s resubmitted New Drug Application (“NDA”) for LEVADEX® orally inhaled migraine drug for the potential acute treatment of migraine in adults has been accepted for filing by the U.S. Food and Drug Administration. | v329152_8k.htm |
| 2012-11-01 | 8-K | 2012-11-01 | 2.02 Results of Operations and Financial Condition | 2.02 On November 1, 2012, MAP Pharmaceuticals, Inc. (“MAP”) issued a press release announcing its financial results for its third quarter ended September 30, 2012. | v327156_8k.htm |
| 2012-10-16 | 8-K | 2012-10-16 | 8.01 Other Events | 8.01 In a press release issued on October 16, 2012, MAP Pharmaceuticals, Inc. (the “Company”) announced that it has resubmitted a New Drug Application to the U.S. Food and Drug Administration for the Company’s LEVADEX orally inhaled migraine drug for the potential acute treatment of migraine. | v325782_8k.htm |
| 2012-08-29 | 8-K | 2012-08-29 | 8.01 Other Events | 8.01 On August 29, 2012, MAP Pharmaceuticals, Inc. (the “Company”) announced that the underwriter of its recent public offering of shares of its common stock pursuant to the Company’s effective shelf registration statement has fully exercised its option to purchase additional shares of common stock. | d401269d8k.htm |
| 2012-08-01 | 8-K | 2012-08-01 | 1.01 Entry into a Material Definitive Agreement; 8.01 Other Events | 1.01 Entry into a Material Definitive Agreement. 8.01 On August 1, 2012, the Company issued a press release announcing the pricing of the underwritten public offering described in Item 1.01 of this Current Report on Form 8-K. A copy of the press release is attached as Exhibit 99.1 hereto and is incorporated herein by reference. | d388649d8k.htm |
| 2012-07-31 | 8-K | 2012-07-31 | 8.01 Other Events | 8.01 On July 31, 2012, MAP Pharmaceuticals, Inc. (the “Company”) announced that it intends to offer shares of the Company’s common stock in a public offering pursuant to the Company’s effective shelf registration statement. | d388667d8k.htm |
| 2012-07-24 | 8-K | 2012-07-24 | 2.02 Results of Operations and Financial Condition | 2.02 On July 24, 2012, MAP Pharmaceuticals, Inc. (“MAP”) issued a press release announcing its financial results for its second quarter ended June 30, 2012. | v319311_8k.htm |
| 2012-06-25 | 8-K | 2012-06-25 | 8.01 Other Events | 8.01 In a press release issued on June 25, 2012, MAP Pharmaceuticals, Inc. (the “Company”) provided an update regarding the meeting held with the U.S. Food and Drug Administration (“FDA”) to discuss the Complete Response Letter to the Company’s New Drug Application for LEVADEX (dihydroergotamine) inhalation aerosol. | d371917d8k.htm |
| 2012-05-18 | 8-K | 2012-05-17 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 The annual meeting of stockholders of MAP Pharmaceuticals, Inc. (the “Company”) was held pursuant to notice on May 17, 2012 for the purposes of voting on the following three proposals, each of which is described in detail in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on April 16, 2012 (the “Proxy”): (1) electing three Class II directors for a three-year term or until the election and qualification of their successors; (2) ratifying the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the 2012 fiscal year; and (3) seeking an advisory (non-binding) vote to approve executive compensation. | d355893d8k.htm |
| 2012-05-04 | 8-K | 2012-05-04 | 2.02 Results of Operations and Financial Condition | 2.02 On May 4, 2012, MAP Pharmaceuticals, Inc. (“MAP”) issued a press release announcing its financial results for its first quarter ended March 31, 2012. | v311877_8k.htm |
| 2012-04-12 | 8-K | 2012-04-12 | 8.01 Other Events | 8.01 In a press release issued on April 12, 2012, MAP Pharmaceuticals, Inc. (the “Company”) announced that the U.S. Food and Drug Administration has scheduled a meeting with the Company in the second quarter to discuss the Complete Response Letter to its New Drug Application for LEVADEX (dihydroergotamine) inhalation aerosol. | d332820d8k.htm |
| 2012-03-29 | 8-K | 2012-03-29 | 2.02 Results of Operations and Financial Condition | 2.02 On March 29, 2012, MAP Pharmaceuticals, Inc. (“MAP”) issued a press release announcing its financial results for its fourth quarter and year ended December 31, 2011. | d325988d8k.htm |
| 2012-03-29 | 8-K | 2012-03-28 | 4.02 Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review | 4.02 On March 28, 2012, the Audit Committee of the Board of Directors of MAP Pharmaceuticals, Inc. (the “Company”) determined, following a review by the Securities and Exchange Commission (“SEC”) of the Company’s Annual Report on Form 10-K for the year ended December 31, 2010 and Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2011 (the “Staff Review”), that the Company will restate its unaudited financial results for the quarters ended March 31, 2011, June 30, 2011 and September 30, 2011. | d324644d8k.htm |
| 2012-03-27 | 8-K | 2012-03-26 | 7.01 Regulation FD Disclosure; 8.01 Other Events | 7.01 In a press release issued on March 26, 2012 and attached hereto as Exhibit 99.1, MAP Pharmaceuticals, Inc. (the “Company”) announced that the U.S. Food and Drug Administration (the “FDA”) has issued a Complete Response Letter to its New Drug Application (NDA) for LEVADEX (dihydroergotamine) inhalation aerosol. 8.01 In a press release issued on March 26, 2012, MAP Pharmaceuticals, Inc. (the “Company”) announced that the U.S. Food and Drug Administration (the “FDA”) has issued a Complete Response Letter to its New Drug Application (NDA) for LEVADEX (dihydroergotamine) inhalation aerosol. | d321452d8k.htm |
| 2012-01-27 | 8-K | 2012-01-25 | 1.01 Entry into a Material Definitive Agreement; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On January 25, 2012, the Compensation Committee of MAP Pharmaceuticals, Inc. (the “Company”) approved the following actions relating to certain of the executive officers of the Company. | d290644d8k.htm |
| 2012-01-17 | 8-K | 2012-01-13 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 (d) Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. | d284105d8k.htm |
| 2011-12-02 | 8-K | 2011-11-29 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | d263921d8k.htm |
| 2011-11-08 | 8-K | 2011-11-08 | 2.02 Results of Operations and Financial Condition | 2.02 On November 8, 2011, MAP Pharmaceuticals, Inc. (“MAP”) issued a press release announcing its financial results for its third quarter ended September 30, 2011. | v239017_8-k.htm |
| 2011-10-17 | 8-K | 2011-10-16 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 (b) Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. | d244546d8k.htm |
| 2011-08-11 | 8-K/A | 2011-05-19 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 On May 24, 2011, MAP Pharmaceuticals, Inc. (“MAP”) filed a Current Report on Form 8-K summarizing the matters voted on at its Annual Meeting of Stockholders held on May 19, 2011 (the “Annual Meeting”) (the “May 24, 2011 Form 8-K”). | d8ka.htm |
| 2011-08-04 | 8-K | 2011-08-04 | 2.02 Results of Operations and Financial Condition | 2.02 On August 4, 2011, MAP Pharmaceuticals, Inc. (“MAP”) issued a press release announcing its financial results for its second quarter ended June 30, 2011. | v230777_8k.htm |
| 2011-08-02 | 8-K | 2011-08-02 | 8.01 Other Events | 8.01 On August 2, 2011, MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) (the “Company”) announced that the Company’s New Drug Application (“NDA”) for LEVADEX® orally inhaled migraine drug for the potential acute treatment of migraine in adults has been accepted for filing by the U.S. Food and Drug Administration. | d8k.htm |
| 2011-05-26 | 8-K | 2011-05-26 | 8.01 Other Events | 8.01 In a press release issued on May 26, 2011, MAP Pharmaceuticals, Inc. (the “Company”) announced that it has submitted a New Drug Application to the U.S. Food and Drug Administration for the Company’s LEVADEX orally inhaled migraine drug for the potential acute treatment of migraine. | d8k.htm |
| 2011-05-24 | 8-K | 2011-05-19 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 The annual meeting of stockholders of MAP Pharmaceuticals, Inc. (the “Company”) was held pursuant to notice on May 19, 2011 for the purposes of: (1) electing two Class I directors for a three-year term or until the election and qualification of their successors; (2) ratifying the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the 2011 fiscal year; (3) seeking an advisory (non-binding) vote to approve executive compensation; and (4) seeking an advisory (non-binding) vote to recommend the frequency of future stockholder voting on executive compensation every one, two or three years. | d8k.htm |
| 2011-05-03 | 8-K | 2011-05-03 | 2.02 Results of Operations and Financial Condition | 2.02 On May 3, 2011, MAP Pharmaceuticals, Inc. (“MAP”) issued a press release announcing its financial results for its first quarter ended March 31, 2011. | v220578_8-k.htm |
| 2011-04-15 | 8-K | 2011-04-11 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On April 11, 2011, Carl S. Goldfischer, M.D., a member of the Board of Directors of MAP Pharmaceuticals, Inc. (the “Company”), notified the Company that he has decided not to seek reelection as a member of the Board of Directors at the Company’s next annual meeting of stockholders, which the Company currently plans to hold on May 19, 2011. | d8k.htm |
| 2011-03-01 | 8-K | 2011-03-01 | 2.02 Results of Operations and Financial Condition | 2.02 On March 1, 2011, MAP Pharmaceuticals, Inc. (“MAP”) issued a press release announcing its financial results for its fourth quarter and full year ended December 31, 2010. | v213016_8-k.htm |
| 2011-02-18 | 8-K | 2011-02-16 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On February 16, 2011, Steven A. Elms tendered his resignation as a member and as Chair of the Board of Directors (the “Board”) of MAP Pharmaceuticals, Inc. (the “Company”), effective as of February 16, 2011. | v211916_8-k.htm |
| 2011-02-16 | 8-K/A | 2011-01-28 | 1.01 Entry into a Material Definitive Agreement | 1.01 On January 31, 2011, MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) (“MAP” or the “Company”) filed a Current Report on Form 8-K (the “Original 8-K”) describing the Collaboration Agreement (the “Collaboration Agreement”) and Co-Promotion Agreement (the “Co-Promotion Agreement,” and together with the Collaboration Agreement, the “Agreements”) with Allergan, Inc., Allergan USA, Inc. and Allergan Sales, LLC (collectively, “Allergan”). | d8ka.htm |
| 2011-02-01 | 8-K | 2011-01-26 | 1.01 Entry into a Material Definitive Agreement; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On January 26, 2011, the Compensation Committee of MAP Pharmaceuticals, Inc. (the “Company”) approved the following actions relating to certain of the executive officers of the Company. | d8k.htm |
| 2011-01-31 | 8-K | 2011-01-28 | 1.01 Entry into a Material Definitive Agreement; 7.01 Regulation FD Disclosure | 1.01 On January 28, 2011, MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) (“MAP” or the “Company”) entered into a Collaboration Agreement (the “Collaboration Agreement”) and a Co-Promotion Agreement (the “Co-Promotion Agreement,” and together with the Collaboration Agreement, the “Agreements”) with Allergan, Inc., Allergan USA, Inc. and Allergan Sales, LLC (collectively, “Allergan”). 7.01 The information in this Item, including Exhibit 99.1 attached hereto, is furnished pursuant to Item 7.01 of this Form 8-K. Consequently, it is not deemed “filed” for the purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section. | d8k.htm |
| 2010-11-08 | 8-K | 2010-11-08 | 8.01 Other Events | 8.01 In a press release issued on November 8, 2010, MAP Pharmaceuticals, Inc. announced that in a clinical trial evaluating whether its LEVADEX™ product candidate causes an increase in QT interval, a supra-therapeutic dose of LEVADEX (approximately three times the anticipated commercial dose) did not increase QTc intervals. | d8k.htm |
| 2010-11-05 | 8-K | 2010-11-05 | 2.02 Results of Operations and Financial Condition | 2.02 On November 5, 2010, MAP Pharmaceuticals, Inc. (“MAP”) issued a press release announcing its financial results for its third quarter ended September 30, 2010. | v200791_8-k.htm |
| 2010-10-04 | 8-K | 2010-10-04 | 8.01 Other Events | 8.01 On October 4, 2010, MAP Pharmaceuticals, Inc. (the “Company”) issued a press release announcing the closing of the underwritten registered offering of 3,450,000 shares of its common stock, including 450,000 shares of its common stock issued pursuant to the full exercise of the over-allotment option granted to the underwriters in the offering, at an offering price of $14.50 per share. | d8k.htm |
| 2010-09-29 | 8-K | 2010-09-29 | 1.01 Entry into a Material Definitive Agreement; 8.01 Other Events | 1.01 On September 29, 2010, MAP Pharmaceuticals, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Lazard Capital Markets LLC, as representative of the several underwriters named therein (collectively, the “Underwriters”), relating to an underwritten registered offering of 3,000,000 shares (the “Shares”) of the Company’s common stock, par value $0.01 per share (the “Common Stock”), at an offering price of $14.50 per share. 8.01 On September 29, 2010, we issued a press release announcing the pricing of the underwritten registered offering described in Item 1.01 of this Current Report on Form 8-K. A copy of this press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. | d8k.htm |
| 2010-09-08 | 8-K | 2010-09-08 | 8.01 Other Events | 8.01 In a press release issued on September 8, 2010, MAP Pharmaceuticals, Inc. (the “Company”) provided an update on the clinical development program for its LEVADEX™ product candidate for the potential treatment of acute migraine, including the completion of patient treatment in certain of its clinical trials. | d8k.htm |
| 2010-08-03 | 8-K | 2010-08-03 | 2.02 Results of Operations and Financial Condition | 2.02 On August 3, 2010, MAP Pharmaceuticals, Inc. (“MAP”) issued a press release announcing its financial results for its second quarter ended June 30, 2010. | v192165_8k.htm |
| 2010-05-21 | 8-K | 2010-05-20 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 The annual meeting of stockholders of MAP Pharmaceuticals, Inc. (the “Company”) was held pursuant to notice on May 20, 2010 for the purposes of: (1) electing three Class III directors for a three-year term or until the election and qualification of their successors; and (2) ratifying the selection of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the 2010 fiscal year. | d8k.htm |
| 2010-05-11 | 8-K | 2010-05-11 | 8.01 Other Events | 8.01 In a press release issued on May 11, 2010, MAP Pharmaceuticals, Inc. (the “Company”) provided an update on the Phase 3 development program for its LEVADEX™ product candidate for the potential treatment of acute migraine. | d8k.htm |
| 2010-05-04 | 8-K | 2010-05-04 | 2.02 Results of Operations and Financial Condition | 2.02 On May 4, 2010, MAP Pharmaceuticals, Inc. (“MAP”) issued a press release announcing its financial results for its first quarter ended March 31, 2010. | d8k.htm |
| 2010-03-02 | 8-K | 2010-03-02 | 2.02 Results of Operations and Financial Condition | 2.02 On March 2, 2010, MAP Pharmaceuticals, Inc. (“MAP”) issued a press release announcing its financial results for its fourth quarter and full year ended December 31, 2009. | d8k.htm |
| 2010-02-04 | 8-K | 2010-02-02 | 1.01 Entry into a Material Definitive Agreement; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On February 2, 2010, the Compensation Committee of MAP Pharmaceuticals, Inc. (the “Company”) approved the following actions relating to certain of the executive officers of the Company. | d8k.htm |
| 2010-01-28 | 8-K | 2010-01-28 | 8.01 Other Events | 8.01 On November 11, 2009, MAP Pharmaceuticals, Inc., a Delaware corporation (the “Company”), entered into a Common Stock Purchase Agreement (the “Purchase Agreement”) with Azimuth Opportunity Ltd. (“Azimuth”), which provides the Company with what is sometimes termed an equity line of credit arrangement. | d8k.htm |
| 2010-01-11 | 8-K | 2010-01-11 | 8.01 Other Events | 8.01 In a press release issued on January 11, 2010, MAP Pharmaceuticals, Inc. (the “Company”) announced that it had been informed by the U.S. Food and Drug Administration (“FDA”) that a second pivotal efficacy study of its LEVADEX™ product candidate for the potential treatment of migraine is not required for the Company’s new drug application submission. | d8k.htm |
| 2009-11-12 | 8-K | 2009-11-11 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | d8k.htm |
| 2009-11-05 | 8-K | 2009-11-05 | 2.02 Results of Operations and Financial Condition | 2.02 On November 5, 2009, MAP Pharmaceuticals, Inc. (“MAP”) issued a press release announcing its financial results for its third quarter ended September 30, 2009. | d8k.htm |
| 2009-10-30 | 8-K | 2009-10-29 | 8.01 Other Events | 8.01 In a press release issued on October 29, 2009, MAP Pharmaceuticals, Inc. (the "Company") reported that the Company had completed a planned interim review of the open-label, long-term safety extension of the Company's Phase 3 FREEDOM 301 clinical trial with the Company's LEVADEX(TM) orally inhaled migraine therapy. | rrd255838.htm |
| 2009-09-10 | 8-K | 2009-09-10 | 7.01 Regulation FD Disclosure; 8.01 Other Events | 7.01 In a press release issued on September 10, 2009 and attached hereto as Exhibit 99.1, MAP Pharmaceuticals, Inc. (the "Company") announced plans to present the analysis of data from the efficacy portion of the first Phase 3 trial of its LEVADEX orally inhaled migraine therapy, currently in development, on Saturday, September 12, 2009 at the 14th Congress of the International Headache Society. 8.01 In a press release issued on September 10, 2009, the Company announced plans to present the analysis of data from the efficacy portion of the first Phase 3 trial of its LEVADEX orally inhaled migraine therapy, currently in development, on Saturday, September 12, 2009 at the 14th Congress of the International Headache Society. | rrd237871.htm |
| 2009-08-06 | 8-K | 2009-08-05 | 1.01 Entry into a Material Definitive Agreement; 8.01 Other Events | 1.01 On August 5, 2009, MAP Pharmaceuticals, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Deutsche Bank Securities Inc., as representative of the several underwriters named in Schedule I thereto (collectively, the “Underwriters”), relating to a public offering of 3,500,000 shares (the “Shares”) of the Company’s common stock, par value $0.01 per share (the “Common Stock”). 8.01 On August 5, 2009, we issued a press release announcing the commencement of the public offering described in Item 1.01 of this Current Report on Form 8-K. On August 6, 2009, we issued a press release announcing the pricing of the public offering described in Item 1.01 of this Current Report on Form 8-K. Copies of these press releases are attached hereto as Exhibit 99.1 and Exhibit 99.2 and are incorporated herein by reference. | d8k.htm |
| 2009-08-03 | 8-K | 2009-08-03 | 2.02 Results of Operations and Financial Condition | 2.02 On August 3, 2009, MAP Pharmaceuticals, Inc. (“MAP”) issued a press release announcing its financial results for its second quarter ended June 30, 2009. | d8k.htm |
| 2009-07-09 | 8-K | 2009-07-08 | 1.02 Termination of a Material Definitive Agreement; 8.01 Other Events | 1.02 On July 8, 2009, MAP Pharmaceuticals, Inc. (the “Company”) received notice from AstraZeneca AB (“AstraZeneca”) of the termination of the License Agreement between the Company and AstraZeneca dated December 19, 2008 (the “License Agreement”), effective immediately. 8.01 In a press release issued on July 9, 2009, the Company announced that on July 8, 2009 it had received notice from AstraZeneca of the termination of the License Agreement between the Company and AstraZeneca dated December 19, 2008, effective immediately. | d8k.htm |
| 2009-05-26 | 8-K | 2009-05-26 | 7.01 Regulation FD Disclosure; 8.01 Other Events | 7.01 In a press release issued on May 26, 2009 and attached hereto as Exhibit 99.1, the Company announced results of the efficacy portion of its initial Phase 3 clinical trial of MAP0004 for the potential treatment of acute migraine. 8.01 In a press release issued on May 26, 2009, MAP Pharmaceuticals, Inc. (the “Company”) announced results of the efficacy portion of its initial Phase 3 clinical trial of MAP0004 for the potential treatment of acute migraine. | d8k.htm |
| 2009-05-07 | 8-K | 2009-05-07 | 2.02 Results of Operations and Financial Condition | 2.02 On May 7, 2009, MAP Pharmaceuticals, Inc. (“MAP”) issued a press release announcing its financial results for its first quarter ended March 31, 2009. | d8k.htm |
| 2009-03-23 | 8-K | 2009-03-19 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On March 19, 2009, MAP Pharmaceuticals, Inc. (the "Company") entered into an agreement (the "Agreement") with Timothy S. Nelson, the Company's President and Chief Executive Officer, which sets forth the severance benefits which Mr. Nelson shall be entitled to receive in the event of a termination of his employment with the Company under certain circumstances. | rrd237965.htm |
| 2009-03-02 | 8-K | 2009-03-02 | 2.02 Results of Operations and Financial Condition | 2.02 On March 2, 2009, MAP Pharmaceuticals, Inc. (“MAP”) issued a press release announcing its financial results for its fourth quarter and full year ended December 31, 2008. | d8k.htm |
| 2009-02-23 | 8-K | 2009-02-23 | 7.01 Regulation FD Disclosure; 8.01 Other Events | 7.01 In a press release issued on February 23, 2009 and attached hereto as Exhibit 99.1, the Company announced results of its initial Phase 3 clinical trial of Unit Dose Budesonide (“UDB”) for the potential treatment of children with asthma. 8.01 In a press release issued on February 23, 2009, MAP Pharmaceuticals, Inc. (the “Company”) announced results of its initial Phase 3 clinical trial of Unit Dose Budesonide (“UDB”) for the potential treatment of children with asthma. | d8k.htm |
| 2009-02-13 | 8-K | 2009-02-11 | 1.01 Entry into a Material Definitive Agreement; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On February 11, 2009, the Compensation Committee of MAP Pharmaceuticals, Inc. (the “Company”) approved the following actions relating to certain of the executive officers of the Company. | d8k.htm |
| 2009-02-03 | 8-K | 2009-02-03 | 8.01 Other Events | 8.01 In a press release issued on February 3, 2009, MAP Pharmaceuticals, Inc. (the “Company”) announced that the waiting period under the Hart-Scott-Rodino Act for the Company’s previously announced License Agreement (the “Agreement”) with ASTRAZENECA AB has expired and that the Agreement has become effective. | d8k.htm |
| 2009-01-26 | 8-K | 2009-01-26 | 8.01 Other Events | 8.01 In a press release issued on January 26, 2009, MAP Pharmaceuticals, Inc. (the “Company”) announced that it has completed patient enrollment in the efficacy portion of a Phase 3 clinical trial of its MAP004 product candidate in patients with migraine. | d8k.htm |
| 2009-01-12 | 8-K | 2009-01-12 | 8.01 Other Events | 8.01 In a press release issued on January 12, 2009, MAP Pharmaceuticals, Inc. (the “Company”) provided an update on the progress of its two Phase 3 clinical programs, for its Unit Dose Budesonide (UDB) product candidate for the potential treatment of children with asthma and for its MAP0004 product candidate for the potential treatment of migraine. | d8k.htm |
| 2008-12-30 | 8-K/A | 2008-12-30 | 1.01 Entry into a Material Definitive Agreement | d8ka.htm | |
| 2008-12-19 | 8-K | 2008-12-19 | 1.01 Entry into a Material Definitive Agreement; 7.01 Regulation FD Disclosure | d8k.htm | |
| 2008-11-12 | 8-K | 2008-11-12 | 2.02 Results of Operations and Financial Condition | d8k.htm | |
| 2008-09-25 | 8-K | 2008-09-24 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | d8k.htm | |
| 2008-09-22 | 8-K | 2008-09-22 | 8.01 Other Events | d8k.htm | |
| 2008-08-12 | 8-K | 2008-08-12 | 2.02 Results of Operations and Financial Condition | d8k.htm | |
| 2008-07-14 | 8-K | 2008-07-14 | 8.01 Other Events | d8k.htm | |
| 2008-06-24 | 8-K | 2008-06-19 | 1.01 Entry into a Material Definitive Agreement; 1.02 Termination of a Material Definitive Agreement; 8.01 Other Events | d8k.htm | |
| 2008-05-12 | 8-K | 2008-05-12 | 2.02 Results of Operations and Financial Condition | d8k.htm | |
| 2008-05-07 | 8-K | 2008-05-02 | 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 8.01 Other Events | d8k.htm | |
| 2008-04-16 | 8-K | 2008-04-14 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | d8k.htm | |
| 2008-03-25 | 8-K | 2008-03-21 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | d8k.htm | |
| 2008-02-28 | 8-K | 2008-02-28 | 2.02 Results of Operations and Financial Condition | d8k.htm | |
| 2008-02-05 | 8-K | 2008-02-02 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | d8k.htm | |
| 2008-01-28 | 8-K | 2008-01-22 | 1.01 Entry into a Material Definitive Agreement; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | d8k.htm | |
| 2008-01-16 | 8-K | 2008-01-16 | 8.01 Other Events | d8k.htm | |
| 2008-01-07 | 8-K | 2008-01-07 | 8.01 Other Events | d8k.htm | |
| 2007-11-07 | 8-K | 2007-11-07 | 2.02 Results of Operations and Financial Condition | d8k.htm | |
| 2007-10-09 | 8-K | 2007-10-08 | 8.01 Other Events | d8k.htm |